Enzalutamide: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Enzalutamide. Educational only — not medical advice.
Labeled uses
XTANDI® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR)
Source: FDA labeling via NIH DailyMed (set b129fdc9…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.